# Multicenter Clinical Study of Anti-VEGF Treatment on High Risk Diabetic Retinopathy (DR)

> **NCT03452657** · PHASE3 · UNKNOWN · sponsor: **Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 118 (estimated)

## Conditions studied

- Diabetic Retinopathy
- Ranibizumab

## Interventions

- **DRUG:** Ranibizumab
- **PROCEDURE:** No drug

## Key facts

- **NCT ID:** NCT03452657
- **Lead sponsor:** Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-04
- **Primary completion:** 2019-06
- **Final completion:** 2020-06
- **Target enrollment:** 118 (ESTIMATED)
- **Last updated:** 2018-03-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03452657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03452657, "Multicenter Clinical Study of Anti-VEGF Treatment on High Risk Diabetic Retinopathy (DR)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03452657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*